These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 17903213)

  • 1. Zoledronate has an antitumor effect and induces actin rearrangement in dexamethasone-resistant myeloma cells.
    Koizumi M; Nakaseko C; Ohwada C; Takeuchi M; Ozawa S; Shimizu N; Cho R; Nishimura M; Saito Y
    Eur J Haematol; 2007 Nov; 79(5):382-91. PubMed ID: 17903213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro.
    Mitrofan LM; Pelkonen J; Mönkkönen J
    Bone; 2009 Dec; 45(6):1153-60. PubMed ID: 19699819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer effects of zoledronic acid against human osteosarcoma cells.
    Kubista B; Trieb K; Sevelda F; Toma C; Arrich F; Heffeter P; Elbling L; Sutterlüty H; Scotlandi K; Kotz R; Micksche M; Berger W
    J Orthop Res; 2006 Jun; 24(6):1145-52. PubMed ID: 16602111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
    Shipman CM; Croucher PI; Russell RG; Helfrich MH; Rogers MJ
    Cancer Res; 1998 Dec; 58(23):5294-7. PubMed ID: 9850051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells.
    Goffinet M; Thoulouzan M; Pradines A; Lajoie-Mazenc I; Weinbaum C; Faye JC; Séronie-Vivien S
    BMC Cancer; 2006 Mar; 6():60. PubMed ID: 16539721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells.
    Yang M; Huang J; Pan HZ; Jin J
    Int J Mol Med; 2008 Oct; 22(4):489-96. PubMed ID: 18813856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells.
    Merrell MA; Wakchoure S; Lehenkari PP; Harris KW; Selander KS
    Eur J Pharmacol; 2007 Sep; 570(1-3):27-37. PubMed ID: 17640631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells.
    Neri P; Yasui H; Hideshima T; Tassone P; Raje N; Catley LP; Ishitsuka K; Blotta S; Kiziltepe T; Ocio EM; Fulciniti M; Kanekal S; Elliott GT; Munshi NC; Anderson KC
    Br J Haematol; 2006 Jul; 134(1):37-44. PubMed ID: 16803565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect.
    Corso A; Ferretti E; Lunghi M; Zappasodi P; Mangiacavalli S; De Amici M; Rusconi C; Varettoni M; Lazzarino M
    Cancer; 2005 Jul; 104(1):118-25. PubMed ID: 15895374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions.
    Okamoto S; Jiang Y; Kawamura K; Shingyoji M; Tada Y; Sekine I; Takiguchi Y; Tatsumi K; Kobayashi H; Shimada H; Hiroshima K; Tagawa M
    Cell Death Dis; 2014 Nov; 5(11):e1517. PubMed ID: 25393473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells.
    Räikkönen J; Mönkkönen H; Auriola S; Mönkkönen J
    Biochem Pharmacol; 2010 Mar; 79(5):777-83. PubMed ID: 19819230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide.
    Ural AU; Yilmaz MI; Avcu F; Pekel A; Zerman M; Nevruz O; Sengul A; Yalcin A
    Int J Hematol; 2003 Dec; 78(5):443-9. PubMed ID: 14704038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-(8-Hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl)propionic acid, a small molecule isocoumarin, potentiates dexamethasone-induced apoptosis of human multiple myeloma cells.
    Agata N; Nogi H; Milhollen M; Kharbanda S; Kufe D
    Cancer Res; 2004 Dec; 64(23):8512-6. PubMed ID: 15574755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of heat-shock protein 27 expression eliminates drug resistance of osteosarcoma to zoledronic acid.
    Morii T; Ohtsuka K; Ohnishi H; Mochizuki K; Satomi K
    Anticancer Res; 2010 Sep; 30(9):3565-71. PubMed ID: 20944138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells.
    Tassone P; Galea E; Forciniti S; Tagliaferri P; Venuta S
    Int J Oncol; 2002 Oct; 21(4):867-73. PubMed ID: 12239628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27.
    Chauhan D; Li G; Auclair D; Hideshima T; Podar K; Mitsiades N; Mitsiades C; Chen LB; Munshi N; Saxena S; Anderson KC
    Apoptosis; 2004 Mar; 9(2):149-55. PubMed ID: 15004512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of the mevalonate pathway in the antiproliferative effect of zoledronate on ACHN renal cell carcinoma cells.
    Fujita M; Tohi M; Sawada K; Yamamoto Y; Nakamura T; Yagami T; Yamamori M; Okamura N
    Oncol Rep; 2012 May; 27(5):1371-6. PubMed ID: 22322451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PC cell-derived growth factor confers resistance to dexamethasone and promotes tumorigenesis in human multiple myeloma.
    Wang W; Hayashi J; Serrero G
    Clin Cancer Res; 2006 Jan; 12(1):49-56. PubMed ID: 16397023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment.
    Derenne S; Amiot M; Barillé S; Collette M; Robillard N; Berthaud P; Harousseau JL; Bataille R
    J Bone Miner Res; 1999 Dec; 14(12):2048-56. PubMed ID: 10620064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.